Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib.
AFP
HCC
PIVKA-II
digital imaging
hepatocellular carcinoma
kinetics
mathematical modeling
regorafenib
sorafenib
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
25 Apr 2021
25 Apr 2021
Historique:
received:
02
04
2021
revised:
17
04
2021
accepted:
19
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
In advanced HCC, tyrosine-kinase inhibitors obtain partial responses (PR) in some patients and complete responses (CR) in a few. Better understanding of the mechanism of response could be achieved by the radiomic approach combining digital imaging and serological biomarkers (α-fetoprotein, AFP and protein induced by vitamin K absence-II, PIVKA-II) kinetics. A physic-mathematical model was developed to investigate cancer cells and vasculature dynamics in three prototype patients receiving sorafenib and/or regorafenib and applied in seven others for validation. Overall four patients showed CR, two PR, two stable-disease (SD) and two progressive-disease (PD). The rate constant of cancer cells production was higher in PD than in PR-SD and CR (median: 0.398 vs. 0.325 vs. 0.316 C × day
Identifiants
pubmed: 33922938
pii: cancers13092064
doi: 10.3390/cancers13092064
pmc: PMC8123288
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Nucl Med. 2015 Mar;56(3):339-46
pubmed: 25678490
Cancer Med. 2021 Feb;10(3):914-922
pubmed: 33481328
Clin Mol Hepatol. 2017 Dec;23(4):340-346
pubmed: 28633200
J Biol Chem. 2005 Feb 25;280(8):6409-15
pubmed: 15582995
Cancer Biomark. 2020;29(2):189-196
pubmed: 32623383
Gut. 2021 Feb;70(2):401-407
pubmed: 32398224
Dig Dis Sci. 2017 Oct;62(10):2923-2931
pubmed: 28815349
Oncology. 2011;81(3-4):251-8
pubmed: 22116493
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
J Biol Chem. 2007 Mar 23;282(12):8741-8
pubmed: 17255102
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Yonsei Med J. 2017 Jan;58(1):1-8
pubmed: 27873489
Cancer Res. 2004 Oct 1;64(19):7099-109
pubmed: 15466206
Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2495-2503
pubmed: 32238405
CPT Pharmacometrics Syst Pharmacol. 2016 Jun;5(6):297-304
pubmed: 27300260
AAPS J. 2015 May;17(3):691-9
pubmed: 25739818
Hepatology. 1993 Oct;18(4):990-7
pubmed: 8406374
Cancers (Basel). 2020 Oct 31;12(11):
pubmed: 33142893
Br J Clin Pharmacol. 2011 Aug;72(2):294-305
pubmed: 21392074
Biomed Res Int. 2013;2013:310427
pubmed: 24455683
Oncotarget. 2017 Sep 20;8(48):84102-84111
pubmed: 29137408
Int J Oncol. 2010 Jan;36(1):161-70
pubmed: 19956845
Eur J Cancer. 2011 Feb;47(3):479-90
pubmed: 21074409
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
World J Gastroenterol. 2014 Nov 7;20(41):15087-97
pubmed: 25386057
Anticancer Res. 2015 Jul;35(7):4037-41
pubmed: 26124352
Hepatology. 2018 Feb;67(2):612-622
pubmed: 28898447
Cancers (Basel). 2020 Oct 20;12(10):
pubmed: 33092015
World J Hepatol. 2020 Dec 27;12(12):1239-1257
pubmed: 33442451
Liver Cancer. 2014 Oct;3(3-4):399-404
pubmed: 26280001
Cancers (Basel). 2020 Apr 07;12(4):
pubmed: 32272656